Webcast

Avecho Biotechnology Investor Briefing – 8 December

December 8, 2021

Avecho Biotechnology Investor Briefing – 8 December

Avecho Biotechnology (ASX: AVE) Webcast Replay

8th December, 2021

Avecho Biotechnology (ASX: AVE) is a pharma innovator offering a world-first drug delivery platform used in the projected US$55 billion cannabidiol market.

As a part of our ‘The Insiders: Meet the CEOs’ series, CEO Dr Paul Gavin, provides valuable insights to the company, its key markets and industry, and future prospects.

Recorded on 8th December 2021 at 12pm (AEDT).

Join the next The Insider: Meet the CEOs webcast

Speak to the Reach Markets team

FEATURED SPEAKER

Dr Paul Gavin

CEO - Avecho Biotechnology Limited (ASX: AVE)

Avecho develops and commercialises innovative human and animal health products using its proprietary drug delivery system Tocopheryl Phosphate Mixture (TPM). TPM is the world’s first and only drug delivery platform produced using a patented process that combines two different forms of tocopheryl phosphate, an enhanced form of vitamin E. The platform increases the bioavailability of drugs it delivers by 4-40 times, thereby increasing the effectiveness of the drug and reducing dosage. Avecho operates in, among others, the global cannabidiol market, which is expected to grow to US$55 billion by 2028.

Speak to the Reach Markets team




What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.